137 related articles for article (PubMed ID: 30834622)
1. Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS).
Marschner N; Frank M; Vach W; Ladda E; Karcher A; Winter S; Jänicke M; Trarbach T
Colorectal Dis; 2019 Jul; 21(7):816-826. PubMed ID: 30834622
[TBL] [Abstract][Full Text] [Related]
2. An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients.
Liang L; Tian J; Yu Y; Wang Z; Peng K; Liu R; Wang Y; Xu X; Li H; Zhuang R; Cui Y; Zhu C; Liu T
Cell Physiol Biochem; 2018; 50(2):768-782. PubMed ID: 30308491
[TBL] [Abstract][Full Text] [Related]
3. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
5. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.
Jary M; Lecomte T; Bouché O; Kim S; Dobi E; Queiroz L; Ghiringhelli F; Etienne H; Léger J; Godet Y; Balland J; Lakkis Z; Adotevi O; Bonnetain F; Borg C; Vernerey D
Int J Cancer; 2016 Nov; 139(10):2325-35. PubMed ID: 27472156
[TBL] [Abstract][Full Text] [Related]
7. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Köhne CH; Cunningham D; Di Costanzo F; Glimelius B; Blijham G; Aranda E; Scheithauer W; Rougier P; Palmer M; Wils J; Baron B; Pignatti F; Schöffski P; Micheel S; Hecker H
Ann Oncol; 2002 Feb; 13(2):308-17. PubMed ID: 11886010
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
[TBL] [Abstract][Full Text] [Related]
9. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
10. Lymph node status as a prognostic factor after palliative resection of primary tumor for patients with metastatic colorectal cancer.
Li Q; Wang C; Li Y; Li X; Xu Y; Cai G; Lian P; Cai S
Oncotarget; 2017 Jul; 8(29):48333-48342. PubMed ID: 28430643
[TBL] [Abstract][Full Text] [Related]
11. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
12. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
[TBL] [Abstract][Full Text] [Related]
13. Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors.
Michl M; Thurmaier J; Schubert-Fritschle G; Wiedemann M; Laubender RP; Nüssler NC; Ruppert R; Kleeff J; Schepp W; Reuter C; Löhe F; Karthaus M; Neumann J; Kirchner T; Engel J; Heinemann V
Clin Colorectal Cancer; 2015 Dec; 14(4):281-90. PubMed ID: 26123495
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
15. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
[TBL] [Abstract][Full Text] [Related]
17. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
Froelich MF; Heinemann V; Sommer WH; Holch JW; Schoeppe F; Hesse N; Baumann AB; Kunz WG; Reiser MF; Ricke J; D'Anastasi M; Stintzing S; Modest DP; Kazmierczak PM; Hofmann FO
Eur Radiol; 2018 Dec; 28(12):5284-5292. PubMed ID: 29882070
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.
Grande R; Natoli C; Ciancola F; Gemma D; Pellegrino A; Pavese I; Garufi C; Di Lauro L; Corsi D; Signorelli D; Sperduti I; Cortese G; Risi E; Morano F; Sergi D; Signorelli C; Ruggeri EM; Zampa G; Russano M; Gamucci T
PLoS One; 2016; 11(7):e0157751. PubMed ID: 27442239
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
